Clinical Trials Logo

Multiple Sclerosis clinical trials

View clinical trials related to Multiple Sclerosis.

Filter by:

NCT ID: NCT01610687 Completed - Multiple Sclerosis Clinical Trials

A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis

Start date: July 2001
Phase: Phase 3
Study type: Interventional

An extension study to evaluate the long-term safety, tolerability and efficacy of GW-1000-02 treatment in multiple sclerosis.

NCT ID: NCT01610310 Completed - Healthy Clinical Trials

Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers

Start date: June 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to characterize the pharmacokinetic (PK) profile, safety, and tolerability of peginterferon beta-1a (BIIB017) delivered by the single-use autoinjector or prefilled syringe (PFS) in healthy volunteers to support the development of the autoinjector.

NCT ID: NCT01606215 Completed - Multiple Sclerosis Clinical Trials

Stem Cells in Rapidly Evolving Active Multiple Sclerosis

STREAMS
Start date: January 2013
Phase: Phase 1/Phase 2
Study type: Interventional

This is a randomised, double-blind crossover study to study the effect of intravenous treatment with autologous (derived from the individuals themselves) mesenchymal stem cells (MSCs) in patients with multiple sclerosis (MS).

NCT ID: NCT01606176 Completed - Pain Clinical Trials

A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin

Start date: March 2002
Phase: Phase 3
Study type: Interventional

To investigate the ability of a cannabis based medicine extract to relieve chronic refractory pain of neurological origin.

NCT ID: NCT01606137 Completed - Pain Clinical Trials

A Study of the Long-term Safety of Sativex Use

Start date: February 2002
Phase: Phase 3
Study type: Interventional

Subjects who had previously received GW-1000-02 in a GW study who opted to continue using it in the long-term were monitored for ongoing tolerability and evidence of clinical benefit.

NCT ID: NCT01604265 Completed - Multiple Sclerosis Clinical Trials

A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis

Start date: March 2002
Phase: Phase 3
Study type: Interventional

To investigate the ability of Sativex to relieve central neuropathic pain in multiple sclerosis subjects.

NCT ID: NCT01601119 Completed - Clinical trials for Relapsing Multiple Sclerosis

Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients

Start date: January 2012
Phase: N/A
Study type: Observational

The objective is to establish the impact of current disease modifying therapies (DMTs) and associated support services on Patient Reported Experience Measures and Patient Reported Outcomes in relation to the treatment and management of Relapsing Multiple Sclerosis in the United Kingdom (UK).

NCT ID: NCT01601080 Completed - Clinical trials for Relapsing Multiple Sclerosis

An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmartâ„¢ Injection Device

READER
Start date: April 2012
Phase: N/A
Study type: Observational

This is an observational, retrospective, UK & Ireland audit measuring patient adherence to Rebif® injections with the RebiSmartâ„¢ injection device. Data will be collected from Multiple Sclerosis (MS) patients who have been prescribed Rebif® and have been using the RebiSmartâ„¢ device for injection for a minimum of 24 months.

NCT ID: NCT01600716 Completed - Multiple Sclerosis Clinical Trials

Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)

Start date: June 13, 2012
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of OnabotulinumtoxinA (BOTOX®) for the treatment of urinary incontinence due to NDO in non-catheterizing patients with MS.

NCT ID: NCT01599234 Completed - Multiple Sclerosis Clinical Trials

A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis

Start date: March 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study was to assess the efficacy of Sativex in relieving symptoms of spasticity in multiple sclerosis